《中国医药科学》杂志欢迎您的投稿!.   今天是:        
刘东坚,姬炳焕,关雪萍.辛伐他汀与瑞舒伐他汀对冠心病患者血脂水平的影响[J].中国医药科学,2022,(20):146-149        基金项目:广东省云浮市科技计划项目(WS202001)
辛伐他汀与瑞舒伐他汀对冠心病患者血脂水平的影响
Effect of simvastatin and rosuvastatin on blood lipid levels in patients with coronary heart disease
  
DOI:
中文关键词:  辛伐他汀;瑞舒伐他汀;冠心病;血脂水平;心绞痛
英文关键词:Simvastatin; Rosuvastatin; Coronary heart disease; Blood lipid level; Angina pectoris
作者单位
刘东坚,姬炳焕,关雪萍 广东省罗定市中医院急诊科,广东罗定 527200 
摘要点击次数: 46
全文下载次数: 159
中文摘要:
      [摘要] 目的 分析辛伐他汀与瑞舒伐他汀对冠心病(CHD)患者血脂水平的影响。 方法 选取罗定市中医院收治的CHD患者120例为研究对象,入院时间2020年6月至2021年6月,采用随机数表法分为A组(n=60)和B组(n=60)。B组患者采用辛伐他汀片治疗,A组患者则运用瑞舒伐他汀片治疗。比较两组治疗后血脂水平及临床指标等。 结果 治疗前,两组血脂指标比较,差异无统计学意义(P > 0.05);治疗后,A组总胆固醇(4.38±0.35)、三酰甘油(1.03±1.87)、低密度脂蛋白胆固醇(2.03±0.47)水平均低于B组的(5.08±0.23)、(1.94±1.42)、(2.94±0.49),高密度脂蛋白胆固醇(1.63±0.27)水平高于B组(1.44±0.19),差异有统计学意义(P < 0.05)。A组心绞痛持续时间(1.38±0.30)和频率(1.03±0.87)均低于B组的(3.08±1.19)、(3.94±0.53),差异有统计学意义(P < 0.05);A组治疗总有效率(98.33%)高于B组(80.00%),A组(8.33%)不良事件发生率低于B组(21.67%),差异有统计学意义(P < 0.05)。 结论 瑞舒伐他汀较辛伐他汀对CHD患者治疗效果显著,能有效改善患者临床症状与血脂指标,且不良反应率低,预后效果良好,具有更高的安全性,可广泛应用于临床。
英文摘要:
      [Abstract] Objective To analyze the effect of simvastatin and rosuvastatin on blood lipid levels in patients with coronary heart disease (CHD). Methods A total of 120 CHD patients admitted to Luoding Hospital of Traditional Chinese Medicine from June 2020 to June 2021 were included in the study and randomly divided into group A (n=60) and group B (n=60) according to the random number table method. Patients in group B were treated with simvastatin tablets, while patients in group A were treated with rosuvastatin tablets. The changes of blood lipid levels and clinical indicators after treatment were compared between the two groups. Results Before treatment, there were no significant differences in blood lipid levels and clinical indexes between the two groups (P > 0.05). After treatment, the levels of TC (4.38±0.35), TG (1.03±1.87) and LDL-C (2.03±0.47) in group A were lower than those in group B (5.08±0.23; 1.94±1.42; 2.94±0.49), and the level of HDL-C (1.63±0.27) in group A was higher than that in group B (1.44±0.19), and the differences were statistically significant(P < 0.05). The duration (1.38±0.30) and frequency (1.03±0.87) of angina pectoris in group A were lower than those in group B (3.08±1.19, 3.94±0.53), and the differences were statistically significant (P < 0.05). The therapeutic effect in group A (98.33%) was higher than that in group B (80.00%), and the adverse reaction rate in group A (8.33%) was lower than that in group B(21.67%), and the differences were statistically significant (P < 0.05). Conclusion Compared with simvastatin, rosuvastatin has more obvious therapeutic effect on CHD patients, which can effectively improve the clinical symptoms and blood lipid indexes of patients, with low adverse reaction rate, good prognosis effect, and higher safety. Therefore, it can be widely used in clinical practice.
查看全文  查看/发表评论  下载PDF阅读器
关闭
关键词: 中国医药科学 中国医学 中国医学科学 中华医学 医学杂志 临床医学杂志 医学期刊 中国预防医学 中华预防医学 预防医学杂志 中国药学 药学杂志
药理杂志 中国中医 中医杂志 中华中医药 中医药杂志 中国医疗 医疗器械杂志 中国中西医结合 中国医药 医药杂志 医药期刊 医药论文 医学论文 科研论文 职称论文
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=FF4EC6B96077DFE7A31AA5B75C05DE254B7AB32594B5FB8DA8F6B8E5C608DC78458EDE5FA18C0155E11A2C1449DBAB9273D385569814ED04D8CC037EAA9D273F370FA76E34AA45C3A06953167B169060248E109E1BDD4F356F944CFA33F5DE47ADE2CB6794F9B0BC&pcid=&cid=&jid=&yid=885CEFEC57DA488F&aid=&vid=&iid=A04140E723CB732E&sid=A020552C37306588&eid=EB552E4CFC85690B&fileno=20220926&flag=1&is_more=0">